Bioventus (BVS) Cash from Operations Growth (3y) (2023 - 2026)
Bioventus (BVS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 9.30% |
| 10 | Bioventus | 964.42 Mn | 934.96 Mn | 105.67 Mn | 22.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 22.56% |
| Mar 28, 2026 | 24.24% |
| Dec 31, 2025 | 105.34% |
| Sep 27, 2025 | 475.39% |
| Jun 28, 2025 | 106.65% |
| Mar 29, 2025 | 2.75% |
| Dec 31, 2024 | 13.78% |
| Sep 28, 2024 | -0.86% |
| Jun 29, 2024 | -4.36% |
| Mar 30, 2024 | 30.70% |
| Dec 31, 2023 | -25.85% |
| Sep 30, 2023 | -35.78% |
| Jul 1, 2023 | 11.35% |
| Apr 1, 2023 | -35.90% |